Cargando…

Correction: Advances in immunotherapy for triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Liu, Yang, Hu, Yueting, Xue, Jinqi, Li, Jingying, Yi, Jiang, Bu, Jiawen, Zhang, Zhenyong, Qiu, Peng, Gu, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500861/ https://www.ncbi.nlm.nih.gov/pubmed/37710293 http://dx.doi.org/10.1186/s12943-023-01858-z

Ejemplares similares

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
por: Ertay, Ayse, et al.
Publicado: (2021)

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Correction: GPR110 promotes progression and metastasis of triple-negative breast cancer
por: Nam, Hye-Jung, et al.
Publicado: (2022)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Targeting ferroptosis, the achilles’ heel of breast cancer: A review
por: Liu, Yang, et al.
Publicado: (2022)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

LIPH promotes metastasis by enriching stem‐like cells in triple‐negative breast cancer
por: Zhang, Yixiao, et al.
Publicado: (2020)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Correction: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
por: Chapman, Margaret P., et al.
Publicado: (2019)

Correction for: A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

KK-LC-1 as a therapeutic target to eliminate ALDH(+) stem cells in triple negative breast cancer
por: Bu, Jiawen, et al.
Publicado: (2023)

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Correction: Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype
Publicado: (2014)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Correction: PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2023)

Correction: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
por: Shao, Fuqiang, et al.
Publicado: (2023)

KAT6A Acetylation of SMAD3 Regulates Myeloid‐Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple‐Negative Breast Cancer
por: Yu, Bo, et al.
Publicado: (2022)

Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
por: Lu, Yi, et al.
Publicado: (2023)

Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers
por: Trošt, Nuša, et al.
Publicado: (2019)

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Correction to: New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
por: Ciocan-Cartita, Cristina Alexandra, et al.
Publicado: (2020)

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
por: Guido, Bruna Cândido, et al.
Publicado: (2022)

Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
por: Singh, Balraj, et al.
Publicado: (2022)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Author Correction: Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2021)

Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer
por: Zhu, Xudong, et al.
Publicado: (2023)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3juiduptibc9o9t4ilcieegrri